Views
4 years ago

80 - A Sayús - Junio 2013

  • Text
  • Bipolar
  • Receptores
  • Respuesta
  • Sistema
  • Antidepresivos
  • Pacientes
  • Antidepressant
  • Cholinergic
  • Bipolares
  • Trastorno
  • Psico
Trastorno Bipolar Respuesta paradojal a la supresión de antidepresivos y neurotransmisión colinérgica

47- Winkelman JW; James

47- Winkelman JW; James L. Serotonergic Antidepressants are Associated with REM Sleep Without Atonia. SLEEP. 2004; 27(2):317-21. 48- Monti J M. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011; 15(4):269-281. 49- Janowsky DS, El-Yousef MK, Davis JM and Sekerke HJ. A cholinergic-adrenergic hypotesis of mania and depression. Lancet. 1972; 2: 632-635. 50- Sokolski KN, DeMet EM. Pupillary cholinergic sensitivity to pilocarpine increases in manic lithium responders. Biol. Psychiatry. 1999; 45: 1580-1584. 51- Sokolski KN, DeMet EM. Cholinergic sensitivity predicts severity of mania. Psychiatry Res. 2000; 95:195-200. 52- Sitaram N, Numberger JL, Gershon ES and Gillin JC. Faster cholinergic REM sleep induction in euthymic patient with primary affective illness. Science.1980; 208: 200-202. 53- Berger M, Riemann D, Höchli D and Spiegel R. The cholinergic rapid eye movement sleep indiction test with RS-86. State or trait marker of depression?. Arch. GenPsychiatry. 1989; 46: 421-428. 54- Nurnberger J, Sitaram N, Gershon ES and Gillin JC. A twin study of cholinergic REM induction. Biol. Psychiatry. 1983a; 18: 1161- 1165. 55- Sitaram N, Dube S, Keshavan M, Davies A and Reynal P. The association of supersensitive cholinergic REM induction and affective illness within pedigrees. J. Psychiatr. Res. 1987; 21: 487-497. 56- Cannon D M, Klaver J K, Gandhi S K, Solorio G, Peck S A, Erickson K, Savitz J, Akula N, Eckelman W C, Furey M L, Sahakian B J, McMahon F J and Drevets W C. Genetic variation in cholinergic-muscarinic-2 receptor gene modulates muscarinic 2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol. Psychiatry. 2011 April; 16(4): 407408. 57- Mitterauer B. Imbalance of glial-neuronal interactions in synapses: a possible mechanism of pathophysiology of bipolar disorder. Neuroscientist. 2004; Jun 10(3):199-206. 58- Gibbons AS. Dysfuction of the Cholinergic Muscarinic Recptors and Bipolar Disorder. European Psychiatry Review. 2011; 4(2): 97- 100. 59- Thomas AJ, Davis S, Ferrier IN, Kalaria RN and O Brien JT. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulated cortex in bipolar disorder. Biol. Psychiatry. 2004; Mar 15 55(6):652-655. 60- Thomsen MS, Weyn A and Mikkelsen JD. Hyppocampal alpha 7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or mayor depressive disorder. Bipolar Disord. 2011 Nov.Dec; 13 (7-8): 701- 707. 61- Hong CG, Lai IC, Liou LL, Tsai SJ. Association study of the human partially duplicated alpha 7 nicotinic acetylcholine receptor genetic variant with bipolar disorder. Neurosci. Lett 2004; 355: 69-72. 62- Moore CM, Breeze J L, Gruber SA, Babb SM, Frederick BB, Villafuerte RA, et al. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulated cortex. Bipolar Disord. 2000; Sep 2 (3Pt2): 207-216. 63- Janowsky DS, Overstreet DS. (2000). The Role of Acetylcholine Mechanism in Affective Disorders. http:// www.acnp.org/g4/ G N 401000095/CH.html 64- Furey ML and Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo controlled clinical trial. Arch. Gen. Psychiatry. 2006; 63: 1121-1129. 65- Drevets WC and Furey ML. Replication of scopolamine´s antidepressant efficacy in mayor depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry. 2010; 67: 432-438. 66- Furey LM, Khanna A, Hoffman EM and Drevets WC. Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in Men. Neuropsychopharmacology. 2010; 35:2479-2488. 67- Nierenberg AA and DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J. Clin. Psychiatry. 2001; 62 (Suppl 16): 5-9. 68- Liu HF, Zhou WH, Xie XH, Cao JL, Gu J and Yang GD. Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats. Sheng li Xue Bao. 2004; 56: 95-100. 69- Gibbs RB, Gabor R, Cox T, and Johnson DA. Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat. Psychoneuroendocrinology. 2004; 29: 741-748. 70- Pongrac JL, Gibbs RB and Defranco DB. Estrogen-mediated regulation of cholinergic expression in basal forebrain neurons requires extracellular-signal-regulated kinase activity. Neuroscience. 2004; 124: 809-816. 71- Daniel JM and Dohanich GP. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA 1 of the hippocampus and the associated improvement in working memory. J. Neurosci. 2001; 21: 6949- 6956. 72- Hartvig P, Nordberg A, Torstenson R, Sjoberg P, Fasth KJ and Langstrom B. Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography. Dement Geriatr. Cog. Disord. 2002; 13: 199-204. 73- Lippielo PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J and Bencherif M. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci. Ther. 2008; 14 (4): 266-77. 36 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015